CASI Pharmaceuticals, Inc. Logo

CASI Pharmaceuticals, Inc.

Develops and commercializes drugs for oncology, transplant, and autoimmune disease.

CASI | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1701-1702, CHINA CENTRAL OFFICE TOWER 1, 100025 BEIJING
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company's primary clinical development program centers on CID-103, an investigational anti-CD38 monoclonal antibody. This therapy is being developed to treat antibody-mediated rejection (AMR) in organ transplant recipients and for various autoimmune diseases, addressing a significant unmet medical need. In addition to its research and development pipeline, CASI maintains a portfolio of commercialized pharmaceutical products, primarily targeting the oncology market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CASI Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CASI Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CASI Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SIGA TECHNOLOGIES INC Logo
Develops antiviral drugs for global health security against biothreats and infectious diseases.
United States of America
SIGA
Silexion Therapeutics Corp Logo
Developing a local drug delivery platform to treat KRAS-driven cancers and solid tumors.
United States of America
SLXN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea
215600
Silo Pharma, Inc. Logo
Develops novel psychedelic & traditional therapies for pain and central nervous system disorders.
United States of America
SILO
SINOVAC BIOTECH LTD Logo
Biopharmaceutical firm developing vaccines against infectious diseases like COVID-19 and Hepatitis.
United States of America
SVA
Sionna Therapeutics, Inc. Logo
Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.
United States of America
SION
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea
326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea
302440
Skye Bioscience, Inc. Logo
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
United States of America
SKYE
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway
SOFTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.